Senior Principal Scientist/Director
Pharmaceutical Sciences, Merck & Co., Inc., Rahway, NJ USA, New Jersey
Dr. Heimbach works at Merck in the Biopharmaceutics & Specialty Dosage Group where he serves as a biopharmaceutics and PBBM/PBPK expert in oral and parenteral drug development. Prior to that Tycho was at Novartis where he lead a global PBPK modeling group in DMPK and served as PBPK and biopharmaceutics expert.
Tycho also served as a co-chair a global team which reviews and makes recommendations and conducts predictions to inform clinical trials, including food -effect studies, within the global biophamaceutics function. He served as cochair on working groups for the PBPK Modeling and the PBPK renal and hepatic impairment WG and the pediatric PBPK WG for the Innovation and Quality in Pharmaceutical Development (IQ) consortium.
Tycho co-authored a workshop summary paper on PBBM (Physiologically Based Biopharmaceutics Modeling) and implemented PBBM for FIH trials. Tycho worked at Pfizer for 14 years in PharmSci and DMPK departments supporting neuroscience and antibacterial projects. Dr. Heimbach contributed to a priori PBPK modeling for 25+clinical trials and has authored/coauthored 15+ IND’s. Dr. Heimbach has been a speaker at 42 national and international conferences. He has authored/coauthored ~60 peer-reviewed publications, 3 book chapters and 2 patents. Dr. Heimbach was recognized as an AAPS Fellow in 2021.
Disclosure information not submitted.
Tuesday, October 18, 2022
8:30 AM – 9:00 AM ET
Tuesday, October 18, 2022
9:00 AM – 11:00 AM ET